Back to HomeSOUTH SAN FRANCISCO, Calif., July 14, 2020 – Presidio Medical, Inc., a clinical-stage medical device company developing a neuromodulation platform technology with an initial indication to treat chronic pain, today announced it has closed $30 million in financing. The financing round was led by Invus Opportunities, with participation from existing investor, Action Potential Venture Capital.
Presidio Medical’s technology is designed to provide pain relief across a broad spectrum of pain types where conventional treatment has failed. Patients who fail or receive minimal relief from standard pain treatment represent an important unmet medical need. The investment will be used to further develop the current technology for the treatment of chronic pain as well as to expand application of the platform to address additional indications.
About Invus Opportunities
Invus Opportunities is a sister fund to The Invus Group, an equity investment firm founded in 1985 with over $8 billion of evergreen capital. Invus Opportunities is focused on partnering with market-leading management teams and investors in private transactions globally. With a differentiated heritage and capital base, Invus Opportunities brings a complementary dimension to growing companies and investor groups seeking to create lasting value. Invus Opportunities both leads rounds of financing and co-invests in syndicated financings, and currently manages over $1.5 billion.
About Presidio Medical
Presidio Medical was founded in 2017 and is headquartered in South San Francisco. The clinical-stage, privately-held medical device company, is developing a transformational neuromodulation technology platform with a first indication in the treatment of chronic pain. For more information, visit www.presidiomedical.com.
Media Contacts:
Presidio Medical, Inc.
media@presidiomedical.com
